In MCL patients refractory both to anti-CD20 rituximab and Bruton tyrosine-kinase (BTK) inhibitors (ibrutinib, acalabrutinib), 67% of patients achieved CR (93% ORR), and PFS was 61% at 12 months, which is unprecedented in this patient population. Here, BTK is linked to mantle cell lymphoma.